Related Experiment Videos
Temodar offers promise for treating astrocytomas.
1Emory University, 1365 Clifton Road NE, Suite B6222 South Clinic, Atlanta, GA 30322, USA. Terri_Armstrong@emory.org
Clinical Journal of Oncology Nursing
|March 23, 2001
Summary
Temodar (temozolomide) shows promise for treating brain tumors and other cancers like metastatic melanoma. This drug offers a convenient, hopeful new therapy option for adult anaplastic astrocytoma patients with minimal side effects.
Area of Science:
- Oncology
- Pharmacology
Background:
- Temodar (temozolomide) is an alkylating agent investigated for various cancer treatments.
- Anaplastic astrocytoma is a type of brain tumor requiring effective therapeutic options.
Purpose of the Study:
- To evaluate the efficacy of Temodar in treating brain tumors, including glioblastoma multiforme.
- To explore Temodar's potential in treating other solid tumors and metastatic melanoma.
Main Methods:
- Clinical research is ongoing to determine Temodar's effectiveness.
- Patient outcomes and side effect profiles are being monitored.
Main Results:
- Temodar demonstrates promise in preliminary research for various solid tumors.
- The drug is being investigated for glioblastoma multiforme and metastatic melanoma.
Conclusions:
- Temodar offers a new, convenient therapeutic option for adult anaplastic astrocytoma patients.
- The drug presents minimal side effects and instills hope for improved cancer treatment outcomes.